Calliditas Therapeutics AB (NAS:CALT)
$ 22 -0.19 (-0.86%) Market Cap: 590.48 Mil Enterprise Value: 589.81 Mil PE Ratio: 0 PB Ratio: 18.64 GF Score: 49/100

Calliditas Therapeutics AB Corporate Analyst Meeting Transcript

Jan 20, 2021 / 12:00PM GMT
Release Date Price: $32.74 (+1.87%)
Lars Frick

Good afternoon. My name is Lars Frick. I come from Börsveckan and I have the honor and pleasure to be moderator today at Calliditas R&D Day.

We have an extensive schedule where we'll present updates and overviews of the latest developments. And during the day, there will be 3 occasions where you, our viewers, are welcome to ask questions, and one is at 2:20 p.m. the other is 3:10 p.m., and then there will be -- well, summary of the questions. If you don't feel that you have something that you want to address specifically, maybe questions of a more general nature then you're more than welcome to ask them at the end of the day.

During the day, we will have several presentators regarding clinical updates, pathophysiology and the basics, marketing strategies and so forth and so on. But first of all, I'm very happy to introduce the CEO of Calliditas, Renee Aguiar-Lucander. Please, the stage is yours.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you, and welcome,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot